{"filing":{"accession_number":"0001193125-26-337944","cik":"0001740279","ticker":"INAB","company_name":"IN8BIO, INC.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"inab-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312526337944/inab-20260806.htm"},"events":[{"id":25593,"run_id":23229,"accession_number":"0001193125-26-337944","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"IN8bio issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, including cash position ($18.0M), R\u0026D expenses ($2.5M), G\u0026A expenses ($2.4M), and net loss ($4.8M or $0.25 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures. The financial statements and operational metrics are material to investors assessing the company's financial condition and progress.","company_name":"IN8BIO, INC.","ticker":"INAB","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26470,"accession_number":"0001193125-26-337944","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"IN8bio issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, including cash position ($18.0M), R\u0026D expenses ($2.5M), G\u0026A expenses ($2.4M), and net loss ($4.8M or $0.25 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures. The financial statements and operational metrics are material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:15:37.396418+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26470,"accession_number":"0001193125-26-337944","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"IN8bio issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, including cash position ($18.0M), R\u0026D expenses ($2.5M), G\u0026A expenses ($2.4M), and net loss ($4.8M or $0.25 per share). The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures. The financial statements and operational metrics are material to investors assessing the company's financial condition and progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:15:37.396418+00:00","company_name":"IN8BIO, INC.","ticker":"INAB","filing_date":"2026-08-06"}]}